Radiotheranostics Market Players:
- TransCode Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Clarity Pharmaceuticals
- Ariceum Therapeutics GmbH
- Novartis AG
- Bayer AG
- Progenics Pharmaceuticals, Inc.
- Telix Pharmacuticals Limited
- ITM Radiopharma
- Life Molecular Imaging
- RadioMedix
- Hitachi, Ltd.
- Chiba University
- Shimadzu Corporation
- Canon Medical System Corporation
- Toshiba Corporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of radiotheranostics is evaluated at USD 7.77 billion.
The market size for the radiotheranostics is projected to reach USD 35.78 billion by the end of 2036, expanding at a CAGR of 16.5% during the forecast period i.e., between 2027-2036.
North America’s radiotheranostics market will secure over 30% share by 2036, driven by increasing use of imaging technologies, precision medicine trends, and investments in cancer research.
Key players in the market include Clarity Pharmaceuticals, Ariceum Therapeutics GmbH, Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc., Telix Pharmacuticals Limited, ITM Radiopharma.
